focus -WSS

focus

author：leisure time 2025-08-12 11:30:08 - browse：84646

Amylyx founders — Justin Klee (left) and Joshua Cohen are the co-founders and co-CEOs of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

Amylyx Pharmaceuticals said Friday that its treatment for ALS, called Relyvrio, failed to provide any benefit for patients in a large clinical trial — a stunning outcome that now has the company considering a voluntary withdrawal of the approved medicine from the market.

“This is really hard for us, and it’s really hard for our team who care so much, but it’s so much harder for people with ALS and their families, and we have to keep that perspective,” said a somber Justin Klee, Amylyx’s co-founder and co-CEO, in an interview with STAT on Thursday evening.

In the Phase 3 study involving 664 people with ALS, Relyvrio failed to outperform a placebo on an ALS functional rating scale that measures the ability to perform daily living tasks, walk, breathe, speak, and swallow. The company did not provide detailed results for the study’s primary goal, but said the calculation for statistical significance was 0.67 — well above the 0.05 threshold for success and an indication that Relyvrio provided no benefit at all.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Alabama frozen embryo ruling has major implications for IVF clinics

WSS

How to keep neuroscience’s past racism from being its future

PBM reform efforts get punted in Congress

Alabama hospital puts IVF treatments on hold

STAT readers on older presidents, polypills, Medicare, and more

Medicare Advantage beneficiaries sue Humana over algorithm use

Dario to buy mental health app maker Twill in cash and stock deal

focus

focus

explore

Trump demands the U.S. pay no more for drugs than other countries … again

In Spain, a hospital brews its own CAR

Wildfire smoke exposes gaps in outdoor worker protections

Carvykti CAR

Malaria cases in Florida and Texas: Here’s what you need to know

SNAP should offer more nutrition education

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Cancer drug shortages should be causing more outrage

Drinking less cuts risk of oral cavity, esophageal cancer: Report

hotspot

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

The Harvard botanist who searched for psychedelics in the Amazon

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Can sheer will power keep patients alive in their dying hours?

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

CRISPR gene editing developments we’re watching in 2024

knowledge

entertainment

knowledge

entertainment